Hemab Raises US$ 55M in Series A Funding

Hemab ApS, a Copenhagen, Denmark-based biotech company developing next generation therapeutics for serious underserved bleeding and thrombosis disorders, closed a US$ 55M Series A financing.

The round was led by Novo Holdings, HealthCap and RA Capital Management. As a result of the financing, Mårten Steen, Partner at HealthCap and Laura Tadvalkar, Principal at RA Capital Management, will join Jørgen Søberg Petersen, Partner at Novo Holdings and Hemab’s Chairman, Camilla Petrycer Hansen, Principal at Novo Seeds, and Thomas Batchelor on the Board of Directors.

Proceeds from the financing will be used to progress the company’s pipeline of monoclonal and bispecific antibody-based therapeutics into later stages of development. The pipeline will initially focus on underserved people living with rare bleeding disorders such as Glanzmann’s Thrombasthenia (GT), with plans to expand into more common disorders of hemostasis and thrombosis. The financing will also enable Hemab to further build the team and expand its operational footprint in Denmark and the US.

Benny Sorensen, MD, PhD, who served on Hemab’s Board of Directors, has been appointed Chief Executive Officer and will be based in the US. Dr Sorensen brings a wealth of patient-centred R&D experience in many therapeutic areas including thrombosis and hemostasis. Until recently, Dr Sorensen served as Head of Clinical Development at Codiak BioSciences and has moved to be on its Scientific Advisory Board. Hemab’s co-founders Johan Henrik Faber, who held leadership positions within hemophilia drug research and development at Novo Nordisk, has been appointed Chief Technology Officer; Søren Bjørn, has been appointed Scientific Advisor; and Thomas Batchelor joins the Board of Directors.

Founded by Johan Henrik Faber, Søren Bjørn, Hans Wandall, Thomas Batchelor and Mads Behrndt and led by Benny Sorensen, MD, PhD, Chief Executive Officer, Hemab is a biotech company developing next generation therapeutics for serious, underserved bleeding and thrombosis disorders. Based in Denmark and the US, the company has exclusive licenses to antibody technologies from both Novo Nordisk A/S and Genmab A/S. Hemab aims to progress its pipeline of monoclonal and bispecific antibody-based therapeutics with the vision to transform the treatment paradigm for blood disease patients – from orphan disorders to broad indications with high unmet need.